Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia
August 09 2021 - 6:00AM
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a
clinical stage immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced that it has
dosed the first TP53-mutated acute myeloid leukemia (AML) patient
with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint
inhibitor of the innate immune system, in combination with
azacitidine.
TTI-622 is a fusion protein that is designed to
block the inhibitory activity of CD47, a molecule that is
overexpressed by a wide variety of tumors. CD47 binds to SIRPα on
macrophages and delivers a “don’t eat me” signal that inhibits the
ability of macrophages to engulf and destroy cancer cells.
Preclinical studies have shown that TTI-622 exhibits anti-tumor
activity against AML cells as a monotherapy that is enhanced when
combined with azacitidine.
“The dosing of this patient marks the third
combination cohort that has been initiated with TTI-622,” commented
Dr. Ingmar Bruns, Trillium’s Chief Medical Officer. “This is our
second study in AML and demonstrates our commitment to these
patients.”
The combination of TTI-622 and azacitidine is
being assessed as part of the ongoing, open-label study
(NCT03530683). Approximately 25 patients with newly diagnosed
TP53-mutated AML will be enrolled. The primary endpoints are safety
and complete response rate.
“There are very few therapeutic options for
TP53-mutated AML patients, and their prognosis is poor,” added Dr.
Bruns. “We believe TTI-622 added to standard-of-care azacitidine
has the potential to improve patient outcomes.”
Trillium continues to build on its robust
foundation and strong cash position and is now executing on its
ambitious Phase 1b/2 program, in multiple patient settings across
hematologic and solid tumor cancers. The company looks forward to
generating a strong flow of data over the next couple of years.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The company’s two clinical
programs, TTI-622 and TTI-621, target CD47, a “don’t eat me”
signal that cancer cells frequently use to evade the immune
system.For more information
visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and applicable United States federal
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. Forward-looking statements in this press release
include express or implied statements regarding the therapeutic
potential and monotherapy activity of our programs, including the
potential for TTI-622 in combination with azacitidine to have a
significant impact on the treatment of acute myeloid leukemia, our
clinical development plans, including the expected timing of the
release of further data on Trillium’s TTI-622 and TTI-621 studies,
and our expectations with respect to the timing of clinical
development milestones, including with respect to enrolling
patients in Phase 1b/2 studies in hematological and solid tumor
malignancies, and our expected cash runway. With respect to the
forward-looking statements contained in this press release,
Trillium has made numerous assumptions regarding, among other
things: the impact of the COVID-19 pandemic on its operations, the
effectiveness and timeliness of preclinical and clinical trials;
and the completeness, accuracy and usefulness of the data. While
Trillium considers these assumptions to be reasonable, these
assumptions are inherently subject to significant scientific,
business, economic, competitive, market and social uncertainties
and contingencies. Additionally, there are known and unknown risk
factors that could cause Trillium's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained in this press release. A
discussion of risks and uncertainties facing Trillium appears in
Trillium's Annual Report on Form 10-K for the year ended December
31, 2020, with the U.S. Securities Exchange Commission, each as
updated by Trillium's continuous disclosure filings, which are
available at www.sedar.com and at www.sec.gov. All
forward-looking statements herein are qualified in their entirety
by this cautionary statement, and Trillium disclaims any obligation
to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, except as required by law.
Company Contact:Rosemary
HarrisonSVP, Corporate Development and StrategyTrillium
Therapeutics Inc. 857-412-7029
x225investors@trilliumtherapeutics.comwww.trilliumtherapeutics.com
Media Relations:Mike BeyerSam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jan 2025 to Feb 2025
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Feb 2024 to Feb 2025